Here is a report on recent news and commentary related to the Supreme Court’s decision yesterday in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. We highlight:
- an article discussing how the Supreme Court’s decision “may make generic drugmakers less vulnerable to patent lawsuits involving so-called ‘skinny labels’”;
- an article similarly reporting how the Supreme Court’s decision “is expected to strengthen legal protections for generic manufacturers that launch products using the Hatch-Waxman Act’s ‘carve-out’ process”;
- a blog post suggesting the Supreme Court’s decision “scolded” the Federal Circuit “for its recent approach” and “has potentially far-reaching implications for the induced infringement standard across sectors”; and
- an article emphasizing that “all nine justices” joined Justice Jackson’s opinion in this “closely watched pharmaceutical patent dispute.”
